Amplified Attention Training (AAT) for Age-related Cognitive Decline

针对与年龄相关的认知衰退的增强注意力训练 (AAT)

• 批准号: 8868870
• 负责人: Thomas VanVleet
• 金额: $ 50.52万
• 依托单位: POSIT SCIENCE CORPORATION
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-15 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8868870
• 关键词: Activities of Daily Living; Aftercare; Age-associated memory impairment; Aging; Attention; Auditory; Behavior Therapy; Code; Cognition; Computer software; Data; Discrimination; Effectiveness; Elderly; Evaluation; Exercise; Feedback; Goals; ICD-9; Independent Living; Individual; Internet; Iowa; Learning; Managed Care; Marketing; Measures; Medical Device; Memory; Minor; Modeling; Modification; Monitor; Neuropsychology; Outcome; Participant; Performance; Phase; Physicians; Population; Psychiatry; Psychologist; Publishing; Quality of life; Randomized Controlled Clinical Trials; Randomized Controlled Trials; Research Personnel; Rewards; Site; Specificity; Stimulus; Time; Training; Training Programs; United States Food and Drug Administration; Universities; Validation; alternative treatment; base; clinically significant; cognitive control; cognitive enhancement; cognitive function; cognitive training; computerized; cost effective; design; effective therapy; executive function; experience; functional outcomes; improved; interest; medical schools; multi-site trial; normal aging; novel; novel strategies; outcome forecast; phase 1 study; phase I trial; primary outcome; programs; prototype; public health relevance; standard of care; standardize measure; sustained attention; trial design

DESCRIPTION (provided by applicant): The goal of the current project is to revise a prototype of a computerized attention training program (Memory Lane-Amplified Attention Training, M-AAT) designed for age-related cognitive decline completed in Phase I, and conduct a multi-site, randomized, controlled trial to establish efficacy in this population. As a group, individuals with age-related cognitive decline tend to have poorer long-term prognosis and are more likely to require managed care than individuals without similar declines. Our recent studies are among the first to demonstrate that M-AAT, targeting sustained attention and cognitive control, can produce lasting benefits. The overall goal of the current project is to measure 3 co-primary outcomes: attention, executive function and functional capacity. Evidence from our Phase I trial shows that M-AAT can improve attention and executive function. At the completion of this project we will have outcomes data sufficient for submission to the FDA for clearance as a medical device indicated for cognitive enhancement in age-related cognitive decline (ICD-9 Code R41.81).

描述（由申请人提供）：当前项目的目标是修改计算机化注意力训练程序（记忆通道放大注意力训练，M-AAT）的原型，该程序设计用于在I期完成的年龄相关认知衰退，并进行多中心，随机，对照试验，以确定在该人群中的疗效。作为一个群体， 与年龄相关的认知能力下降往往具有较差的长期预后，并且比没有类似下降的个体更可能需要管理式护理。我们最近的研究是第一批证明M-AAT，针对持续的注意力和认知控制，可以产生持久的好处。 本项目的总体目标是测量3个共同主要结果：注意力、执行功能和功能能力。我们第一阶段试验的证据表明，M-AAT可以改善注意力和执行功能。在本项目完成时，我们将获得足够的结局数据，以提交给FDA，作为适用于增强年龄相关认知下降（ICD-9代码R41.81）的认知的医疗器械进行批准。